The importance of the prevention of treatment induced neutropenia in patients with malignant neoplasms of the head and neck
Hematological toxicity is the most common complication of chemotherapy. The most dangerous manifestation of hematological toxicity is febrile neutropenia (FN). FN reduces survival, increases the risk of death, the frequency of infectious complications, hospitalizations, the cost of treatment. The ri...
Main Author: | Editorial Board |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IP Habib O.N.
2021-08-01
|
Series: | Современная онкология |
Subjects: | |
Online Access: | https://modernonco.orscience.ru/1815-1434/article/viewFile/77948/58537 |
Similar Items
-
Lipegfilgrastim in patients with chemotherapy-induced neutropenia
by: G. D. Petrova, et al.
Published: (2015-12-01) -
Cost-effectiveness of empegfilgrastim (Extimia®) for the prevention of severe neutropenia in patients with malignant neoplasm of female breast
by: A V Rudakova, et al.
Published: (2016-06-01) -
Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar
by: Schwartzberg LS, et al.
Published: (2018-09-01) -
Experience in prevention of neutropenia in patients with disseminated soft tissue sarcomas receiving polychemotherapy
by: L Yu Vladimirova, et al.
Published: (2016-09-01) -
Efficacy and safety of extimia® (empegfilgrastim): results of a double-blind controlled phase iii study in patients with diagnosis «breast cancer» receiving myelosuppressive chemotherapy
by: P V Krivorotko, et al.
Published: (2015-06-01)